Leerink Partners analyst Jonathan Chang maintained a Buy rating on Revolution Medicines on Wednesday, setting a price target of $38, which is approximately 15.75% above the present share price of $32.83.
Chang expects Revolution Medicines to post earnings per share (EPS) of -$0.60 for the fourth quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Moderate Buy rating of shares in Revolution Medicines, with an average price target of $36.67.
The analysts price targets range from a high of $38 to a low of $34.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $8.7 million and a net profit of -$44.54 million. The company's market cap is $2.42 billion.
According to TipRanks.com, Leerink Partners analyst Jonathan Chang is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 2.8% and a 34.82% success rate.
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood (NYSE:RWT) City, CA.